AUA releases updated BPH guideline addressing new treatments
In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.
A new AUA guideline on the management of lower urinary tract symptoms due to BPH focuses on surgical treatments, including newer minimally invasive procedures. In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.
Dr. Kaplan, of the Icahn School of Medicine at Mount Sinai in New York and a member of the panel that developed the guideline, discusses new FDA-approved therapies, one treatment that is no longer recommended, and the use of imaging to make a proper diagnosis prior to treatment. He was interviewed by Urology Times Content Channel Director Richard R. Kerr.
Dr. Kaplan is a consultant/adviser to Astellas, ProVerum Medical, ProArc, Zenflow, Serenity, Allium, Avadel, and Nymox and serves in a leadership position for Medivizor, EcoFusion, and AvantCourse.
